Pri­do­pi­dine is still a mess in lat­est Hunt­ing­ton’s study, but Te­va maps PhI­II

Six years ago a Dan­ish com­pa­ny called Neu­roSearch en­joyed a few days in the sun when it said its ex­per­i­men­tal drug for Hunt­ing­ton’s diease, Huntex­il (pri­do­pi­dine), had scored pos­i­tive da­ta for im­prov­ing mo­tor func­tions in pa­tients in a Phase III study. But a few weeks lat­er the com­pa­ny was bat­tered by a re­assess­ment of the da­ta, which con­clud­ed that the drug had failed.

Neu­roSearch nev­er re­cov­ered from that set­back. But Te­va in-li­censed the drug. And this week it un­veiled new Phase II da­ta on Huntex­il, which con­tin­ues to per­form un­even­ly in clin­i­cal stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER